Merck: encouraging phase III results in HIV

(CercleFinance.com) - On Thursday, Merck reported encouraging Phase III results for its experimental once-daily oral drug for HIV-1 patients.


The US pharmaceutical giant reports that the combination of doravirine and islatravir (DOR/ISL) met its efficacy endpoint, based on HIV-1 RNA greater than or equal to 500 copies/ml after 48 weeks of treatment, in two trials, one in comparison with standard antiretroviral therapy and the other in comparison with Gilead's Biktarvy, which combines three molecules.

In the U.S., doravirine is already approved for the treatment of HIV-1 in combination with other antiretrovirals, both as a single drug under the brand name Pifeltro and as part of a triple therapy in tablet form with lamivudine and tenofovir disoproxil fumarate.

Combined with islatravir, it is expected to offer a potent effect, an effective barrier against resistance, a favorable drug resistance profile and a prolonged half-life.

Copyright (c) 2024 CercleFinance.com. All rights reserved.